EOM Pharmaceuticals Holdings, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. The company’s lead compound is EOM613, a pe... EOM Pharmaceuticals Holdings, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. The company’s lead compound is EOM613, a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects that has completed Phase 2 clinical trials for the treatment of cancer cachexia, AIDS/cancer cachexia, HIV/AIDS, and rheumatoid arthritis, as well as in Phase ½ a clinical trial to treat infectious diseases, such as COVID-19. It also develops EOM 147, an investigational broad-spectrum aminosterol with an intracellular mechanism that has completed Phase 2 clinical trial for the treatment of age-related macular degeneration, diabetic retinopathy, and macular edema due to retinal vain occlusion. EOM Pharmaceuticals Holdings, Inc. was founded in 2020 and is headquartered in Montvale, New Jersey. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0699 | -25.8984809189 | 0.2699 | 0.27 | 0.1901 | 5679 | 0.24265945 | CS |
| 4 | 0.1179 | 143.605359318 | 0.0821 | 0.27 | 0.0821 | 31869 | 0.16500071 | CS |
| 12 | 0.0401 | 25.0781738587 | 0.1599 | 0.27 | 0.075 | 12761 | 0.15504035 | CS |
| 26 | 0.1094 | 120.750551876 | 0.0906 | 0.27 | 0.071 | 8567 | 0.13889917 | CS |
| 52 | 0.0955 | 91.3875598086 | 0.1045 | 0.3399 | 0.036 | 9939 | 0.11901783 | CS |
| 156 | -0.14 | -41.1764705882 | 0.34 | 0.4 | 0.0123 | 6140 | 0.14862588 | CS |
| 260 | -0.41 | -67.2131147541 | 0.61 | 0.94 | 0.0123 | 6672 | 0.30660192 | CS |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。